Abliva AB (Sweden) Performance
| ABLI Stock | SEK 0.43 0.01 2.38% |
Abliva AB holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 4.49, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abliva AB will likely underperform. Use Abliva AB coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to analyze future returns on Abliva AB.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Abliva AB are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Abliva AB unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 61.6 M | |
| Total Cashflows From Investing Activities | -1.1 M |
Abliva |
Abliva AB Relative Risk vs. Return Landscape
If you would invest 15.00 in Abliva AB on October 11, 2024 and sell it today you would earn a total of 28.00 from holding Abliva AB or generate 186.67% return on investment over 90 days. Abliva AB is generating 3.4306% of daily returns and assumes 26.4975% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Abliva on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Abliva AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abliva AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abliva AB, and traders can use it to determine the average amount a Abliva AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1295
| Best Portfolio | Best Equity | |||
| Good Returns | ABLI | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.5 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.43 actual daily | 68 68% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Abliva AB is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abliva AB by adding it to a well-diversified portfolio.
Abliva AB Fundamentals Growth
Abliva Stock prices reflect investors' perceptions of the future prospects and financial health of Abliva AB, and Abliva AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abliva Stock performance.
| Return On Equity | -0.8 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 103.38 M | |||
| Shares Outstanding | 1.06 B | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 2,681 X | |||
| Revenue | 151 K | |||
| EBITDA | (120.82 M) | |||
| Cash And Equivalents | 47.98 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 92 K | |||
| Book Value Per Share | 0.29 X | |||
| Cash Flow From Operations | (114.08 M) | |||
| Earnings Per Share | (0.31) X | |||
| Total Asset | 58.92 M | |||
About Abliva AB Performance
Assessing Abliva AB's fundamental ratios provides investors with valuable insights into Abliva AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Abliva AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Abliva AB , a pharmaceutical company, engages in the research and development of mitochondrial medicine. Abliva AB was incorporated in 2000 and is headquartered in Lund, Sweden. Abliva AB is traded on Stockholm Stock Exchange in Sweden.Things to note about Abliva AB performance evaluation
Checking the ongoing alerts about Abliva AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abliva AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abliva AB is way too risky over 90 days horizon | |
| Abliva AB has some characteristics of a very speculative penny stock | |
| Abliva AB appears to be risky and price may revert if volatility continues | |
| Abliva AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 151 K. Net Loss for the year was (123.49 M) with loss before overhead, payroll, taxes, and interest of (103.54 M). | |
| Abliva AB has accumulated about 47.98 M in cash with (114.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. |
- Analyzing Abliva AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abliva AB's stock is overvalued or undervalued compared to its peers.
- Examining Abliva AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abliva AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abliva AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abliva AB's stock. These opinions can provide insight into Abliva AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Abliva Stock Analysis
When running Abliva AB's price analysis, check to measure Abliva AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abliva AB is operating at the current time. Most of Abliva AB's value examination focuses on studying past and present price action to predict the probability of Abliva AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abliva AB's price. Additionally, you may evaluate how the addition of Abliva AB to your portfolios can decrease your overall portfolio volatility.